Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, July 20, 2018

Omega-3 fats show minimal effect on CV health, mortality

Impossible to tell if this is true. Supplements have no guarantee of purity. What do you expect when the fucking stupidity of the US Congress passes the Dietary Supplement Health and Education Act of 1994 (DSHEA): (DSHEA) defined dietary supplements as a category of food, which put them under different regulations than drugs.
https://www.healio.com/cardiology/chd-prevention/news/online/%7Bd2cdda40-416c-48ce-9aee-86e978451ac9%7D/omega-3-fats-show-minimal-effect-on-cv-health-mortality?
An increased intake of eicosapentaenoic acid and docosahexaenoic acid from omega-3 fats had minimal or no effect on CV health or mortality, according to a review published in the Cochrane Library.
“We can be confident in the findings of this review, which go against the popular belief that long-chain omega-3 supplements protect the heart,” Lee Hooper, PhD, reader in research synthesis, nutrition and hydration at University of East Anglia Norwich Medical School in the United Kingdom, said in a press release. “This large systematic review included information from many thousands of people over long periods. Despite all this information, we don’t see protective effects.”
Asmaa S. Abdelhamid, MD, MSc, research fellow at University of East Anglia Norwich Medical School, and colleagues analyzed data of 112,059 participants from 79 randomized controlled trials that compared the effects of an increase in long-chain omega-3 and alpha-linolenic acid intake with usual or lower intake. Trials included in this review lasted for at least 12 months.
Increased intake of long-chain omega-3 had little to no effect on CV mortality (RR = 0.95; 95% CI, 0.87-1.03), all-cause mortality (RR = 0.98; 95% CI, 0.9-1.03), CHD mortality (RR = 0.93; 95% CI, 0.79-1.09) and CV events (RR = 0.99; 95% CI, 0.94-1.04). It also had minimal or no effect on the risk for arrhythmia (RR = 0.97; 95% CI, 0.9-1.05) and stroke (RR = 1.06; 95% CI, 0.96-1.16).
Long-chain omega-3 reduced the risk for CHD events (RR = 0.93; 95% CI, 0.88-0.97), although this effect was not seen in sensitivity analyses.
An increased intake in alpha-linolenic acid had a minimal effect on CV mortality (RR = 0.96; 95% CI, 0.74-1.25), all-cause mortality (RR = 1.01; 95% CI, 0.84-1.2) and CHD events (RR = 1; 95% CI, 0.8-1.22). A slight reduction in the risk for CV events was seen with increased intake of alpha-linolenic acid (RR = 0.95; 95% CI, 0.83-1.07), and it has the potential to reduce the risk for CHD mortality (RR = 0.95; 95% CI, 0.72-1.26) and arrhythmia (RR = 0.79; 95% CI, 0.57-1.1). The effect it had on stroke was unclear.
“There are several large ongoing trials of supplemental long-chain omega-3 fats,” Abdelhamid and colleagues wrote. “We suggest that given the lack of convincing effects suggested for omega-3 fats in the large number of trials to date, no further trials should be initiated until the ongoing trials have reports. Further large and high-quality trials of [alpha-linolenic acid] carried out in lower and higher income countries and that assess baseline [alpha-linolenic acid] intake and use biomarkers to assess compliance would be helpful to clarify the cardiovascular effects of [alpha-linolenic acid].” – by Darlene Dobkowski

1 comment:

  1. These huge studies include tons of healthy people which can mask the effects of treatment for high risk people.

    ReplyDelete